Problems of variable biomarker evaluation in stratified medicine research—A case study of ERCC1 in non-small-cell lung cancer  by Malottki, Kinga et al.
P
r
K
A
a
o
b
c
d
e
U
a
A
R
R
1
A
K
E
H
B
D
A
C
N
C
ﬂ
e
p
m
I
i
h
0Lung Cancer 92 (2016) 1–7
Contents lists available at ScienceDirect
Lung  Cancer
jou rn al hom epage: www.elsev ier .com/ locate / lungcan
roblems  of  variable  biomarker  evaluation  in  stratiﬁed  medicine
esearch—A  case  study  of  ERCC1  in  non-small-cell  lung  cancer
inga  Malottkia,∗,  Sanjay  Popatb,  Jonathan  J.  Deeksc, Richard  D.  Rileyd,
ndrew  G.  Nicholsone, Lucinda  Billinghama
Cancer Research UK Clinical Trials Unit (CRCTU), MRC Midland Hub for Trials Methodology Research, Institute of Cancer and Genomic Sciences, University
f  Birmingham, United Kingdom
Department of Medicine, Royal Marsden Hospital, London SW3  6JJ, United Kingdom
Institute of Applied Health Research, University of Birmingham, United Kingdom
Research Institute for Primary Care and Health Sciences, Keele University, United Kingdom
Department of Histopathology, Royal Brompton and Hareﬁeld NHS Foundation Trust and National heart and Lung Institute, Imperial College, London,
nited  Kingdom
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 15 September 2015
eceived in revised form
8 November 2015
ccepted 23 November 2015
eywords:
RCC1 protein
uman
iological markers
rug therapy
ntineoplastic therapy
arcinoma
on-small-cell lung
linical trials as topic
a  b  s  t  r  a  c  t
Objectives:  Consistency  of  procedures  for the  evaluation  of a predictive  biomarker  (including  sample
collection,  processing,  assay  and  scoring  system)  based  on  adequate  evidence  is necessary  to implement
research  ﬁndings  in  clinical  practice.  As a case  study  we  evaluated  how  a particular  predictive  biomarker,
ERCC1,  was  assessed  in research  on platinum-based  chemotherapy  in non-small-cell  lung  cancer  and
what  motivated  the  choice  of  procedure.
Materials  and methods:  A systematic  review  of studies  completed  since  2007  and  ongoing  was  undertaken.
Questionnaires  on  details  of  ERCC1  evaluation  procedures  and  the  rationale  for  their  choice  were  sent  to
contacts  of  identiﬁed  studies.
Results:  Thirty-three  studies  of platinum-based  chemotherapy  in non-small-cell  lung  cancer  using  ERCC1
were identiﬁed.  A reply  to  the  questionnaire  was  received  for 16  studies.  Procedures  for ERCC1  evaluation
varied  substantially  and  included  reverse  transcriptase  quantitative  polymerase  chain  reaction  (nine
studies),  immunohistochemistry  (ﬁve  studies)  and other  methods  (multiple  methods–two  studies,  NER
polymorphism–one  study).  In  ﬁve  studies  ERCC1  use  was  planned,  but not  undertaken.  In nine  data  was
insufﬁcient  to identify  the  procedure.  For  each  assay  there  was  variation  across  studies  in  the  details  of
the laboratory  techniques,  scoring  systems  and  methods  for obtaining  samples.
Conclusions:  We  found  large  variation  across  studies  in ERCC1  evaluation  procedures.  This  will limit
the  future  comparability  of  results  between  these  different  studies.  To enable  evidence-based  clinical
practice,  consensus  is  needed  on a validated  procedure  to assess  a predictive  biomarker  in the  early
phase  of  research.  We  believe  that  ERCC1  is  not  untypical  of  biomarkers  being  investigated  for  stratiﬁed
medicine.
© 2015  The  Authors.  Published  by  Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the  CC  BYAbbreviations: ERCC1, excision repair cross-complementation group 1; FISH,
uorescence in situ hybridization; IHC, immunohistochemistry; NER, nucleotide
xcision repair; NR, not reported; NSCLC, non-small-cell lung cancer; PD-L1,
rogrammed-death ligand 1; RTqPCR, reverse transcriptase quantitative poly-
erase chain reactio.
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ttp://dx.doi.org/10.1016/j.lungcan.2015.11.017
169-5002/© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access license  (http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Lung cancer is one of the leading causes of cancer mortality
globally [1–3]. The majority of patients have non-small-cell lung
cancer (NSCLC) histology [3,4]. Prognosis in these patients is gen-
erally poor [2,4], with a ﬁve year survival of about 5% for advanced
NSCLC and about 15% irrespective of stage [3]. In spite of develop-
ment of new, targeted treatments, platinum-based chemotherapy
remains a major part of NSCLC care [2,4–6].
The effectiveness of platinum-based chemotherapy is however
limited [1,7], with resistance to treatment resulting in little or no
beneﬁt and potentially unnecessary toxicity in some patients [8].
article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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n a signiﬁcant number of patients, identiﬁcation of biomarkers
redictive of resistance to platinum-based chemotherapy could
otentially result in avoiding unnecessary treatment, as well as bet-
er allocation of healthcare resources. Expression of excision repair
ross-complementation group 1 (ERCC1) gene has been suggested
s a biomarker potentially relevant to prediction of response to
latinum-based chemotherapy [2].
The use of predictive biomarkers is becoming more common.
he accuracy and replicability of the procedures used to evaluate
hese biomarkers (including sample collection, processing, assay,
coring system and threshold) are therefore crucial. The use of
tandardised procedures is important to facilitate combination of
esults of multiple studies in a meta-analysis and implementation
f their ﬁndings in clinical practice. There are however reasons to
elieve that in practice there may  be little consistency in these
rocedures. A review of published papers investigating ERCC1
xpression to predict response to platinum-based chemotherapy
n lung cancer found that there was large variability in the assays
sed [2]. This review was published in 2011, thus including rela-
ively early ERCC1 evaluations. There was a possibility that more
ecent research practice has become more harmonised.
ERCC1 was also chosen as a case study, as the research investi-
ating it as a potential predictive biomarker was relatively recent
nd therefore likely to illustrate current practice. An interesting
evelopment was that it was suggested that currently there may  be
o laboratory procedure capable of identifying the ERCC1 isoform
hat may  be responsible for resistance to cisplatin [7].
The aim of this systematic review undertaken in 2013 and subse-
uent questionnaire was to investigate the consistency of methods
or evaluation of ERCC1 as a biomarker predictive of response to
latinum-based chemotherapy in ongoing or completed since 2007
tudies in NSCLC, and to investigate the rationale for choice of a
peciﬁc method. This project sets out to provide a case study of
urrent research practice, from which lessons can be learned that
ay  apply to a wider context of predictive biomarker research.
. Materials and methods
Searches for studies completed since 2007 and ongoing were
ndertaken on 26 March 2013 in ClinicalTrials.gov, WHO  and
he Controlled-Trials databases. Search terms were based on the
atient population (NSCLC), the biomarker (ERCC1) and treat-
ent (platinum-based chemotherapy). The full search strategies
re available in the online supplement.
Studies meeting the following criteria were included:
Population: patients with NSCLC (any stage).
Intervention: at least one of the study arms included platinum-
based chemotherapy.
Biomarker assay: any assay measuring ERCC1 expression or
nucleotide excision repair (NER) gene expression in tumour tis-
sue or blood.
Outcome: any.
Study: any ongoing study or completed/terminated after 1st
January 2007.
Titles of studies were screened by two independent reviewers
KM and LB) and those clearly not meeting the inclusion crite-
ia were excluded. For the remaining studies full records obtained
rom databases of ongoing trials were considered for inclusion by
wo independent reviewers (KM and LB). Studies were included if
hey met  all inclusion criteria. Studies only specifying the inter-
ention as chemotherapy or systemic therapy were also included
f all the remaining criteria were met. Disagreements betweenncer 92 (2016) 1–7
reviewers were resolved by discussion and in two cases by seeking
further information on the studies in internet searches.
For all included studies, information was  extracted from the
databases on: study phase, design, planned sample size, status
(ongoing, completed, terminated or withdrawn), start and planned
end date, primary outcome, patient inclusion criteria, intervention,
ERCC1 evaluation, location, sponsor and contact details.
A questionnaire asking about the details of ERCC1 evaluation
procedures and reasons for their choice was  prepared in collabo-
ration with clinical and pathology experts and sent to contacts for
each included study, the sponsor or for published studies the corre-
sponding author (whichever was available). The questionnaire was
sent on 5th August 2013 and if no reply was received, again on 28th
January 2014. For completed studies searches for publications were
also undertaken.
Data obtained from databases of ongoing trials and replies
received were summarised using descriptive analysis. No addi-
tional information was  obtained through searches for published
studies.
3. Results
3.1. Details of studies included in the systematic review
The searches identiﬁed 730 unique records in databases of clin-
ical trials. The review process is presented in detail in Fig. 1, leading
to 33 studies being included in the study.
Eighteen of the included studies were ongoing, eight completed,
two terminated early and one withdrawn prior to enrolment. The
status of four studies was  unknown. Nine of the included studies
were conducted in Asia, eight in Europe, 13 in North America, one
included locations in Europe and North America and for two the
location was  not reported. The phase and size of studies together
with design is shown in Fig. 2.
There were two  key types of study design (see Fig. 2 cap-
tion for details). In 19 studies ERCC1 was  not an integral part of
the study design, but a correlation between the biomarker sta-
tus and treatment outcome was  investigated (correlative studies).
The remainder used ERCC1 as an integral part of the design: thir-
teen used ERCC1 alone or in combination with other biomarkers to
determine treatment strategy (biomarker strategy design) and one
study used ERCC1 to stratify randomisation.
As expected, single arm correlative studies were most fre-
quently early phase studies (phase 0, I and II). Nine of 15 phase II
studies reported testing a strategy that was  based on ERCC1 and in
some cases also included other biomarkers. Phase III trials included
one correlative RCT, one RCT stratiﬁed by ERCC1 and three RCTs
using ERCC1 to select a treatment strategy. The phase IV study was
a biomarker-based strategy RCT.
Detailed characteristics of included studies are reported in the
online Supplement.
3.2. ERCC1 Information on all included studies
The procedures for evaluation of ERCC1 varied across stud-
ies (Fig. 3). Data was available in sufﬁcient detail to enable the
identiﬁcation of the laboratory procedure used in 24 of the 33 stud-
ies. Of these, reverse transcriptase quantitative polymerase chain
reaction (RTqPCR) was  used in nine (38%) and immunohistochem-
istry (IHC) in ﬁve (21%) studies. Two  studies reported the use of
multiple methods. In one immunoﬂuorescence-based automated
quantitative analysis for in situ expression was used as the primary
assay and if additional samples were available, RT-PCR, RTqPCR,
polymorphism analysis and tissue microarray analysis of genes
associated with DNA synthesis, damage repair, and drug efﬁcacy
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Clinical Trial s.gov  - 317 
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screened
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iFig. 1. Flow diagram outlining the results of searches in ongoing tria
ere also undertaken. In another study both ﬂuorescence in situ
ybridization (FISH) and IHC were used. One study investigated
ER polymorphism. In ﬁve studies, although initially planned, no
RCC1 evaluation was undertaken.
The type of specimen used also varied, as shown in Fig. 3, with
iopsy being the most frequent.
It appears that irrespective of the study phase there was  vari-
tion in the laboratory procedures used for evaluation of ERCC1
tatus. There was no relationship between the year of study initia-
ion and laboratory procedure (data in Supplementary ﬁgure).
.3. Additional Information on ERCC1 evaluation obtained from
he questionnaire
A reply to the questionnaire was received for 16 studies (shown
n Fig. 2). Five of these did not undertake ERCC1 evaluation,abases, review of studies and replies received for the questionnaire.
although initially planned (reasons included: early study termina-
tion, insufﬁcient samples, lack of funding).
In the 11 studies that evaluated ERCC1, it was prospective
(prior to patients receiving treatment) in all eight studies using the
biomarker to identify treatment strategy or stratify randomisation.
Three studies were correlative and all of these evaluated ERCC1
retrospectively and blind to patient outcome. In studies assessing
ERCC1 prospectively the time needed for results to be returned to
the treating physician varied between a minimum of one to two
days to 14 days. It was however usually not indicated if this time
was measured from patient enrolment or receipt of sample by the
laboratory.Nine of the replies reported the site of ERCC1 evaluation: in
seven it was  a central laboratory and in two an individual hospital.
Of the ﬁve studies where ERCC1 was  evaluated with IHC, the
monoclonal 8F1 antibody clone was  used in three (in 1:300 dilution
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iStraﬁed design: paents were included in the tri al irr espec ve of their biomark er status, randomisa
Fig. 2. Planned trial sample size and design with
n two and not reported in one), the ZSGB-Bio, China antibody clone
n one (in 1:50 dilution) and it was not reported in one. Ancillary
ethods were reported for two of these studies and were: auto-
ated ICH stainer in one study and exposing samples to 10 mM
itrate buffer (pH 6.0) and then heating for 30 min  in a water bath
n the other.
To obtain an IHC expression score four studies used the H-score
nd one study used the Allred Quick Score. The thresholds for clas-
ifying patients as positive were:
H-score 1 and above in two studies,
median H-score in one study (retrospective analysis),
Allred Quick Score 6 and above.
In six studies which used RTqPCR it appears that different sets
f primers were used, although this could not be established with
ertainty (details shown in Table 1). -actin on its own  was used as
he reference gene in four studies. In one study -actin was  used
ogether with PGK and in one study 18SrRNA was used. Only two
tudies reported the method used to calculate the quantity of ERCC1
NA and it was the CT method. The thresholds for classifying
atients as positive were:
median in three studies,
ratio of ERCC1 to reference gene transcripts of 1.7 in one study,
8.7 (no further details provided) in one study,
in one study the threshold was not clearly reported.
The proportion of patients classed as ERCC1 positive was
eported for two studies using RTqPCR and was 0.6 and 0.64..4. Rationale for choice of ERCC1 procedures
The rationale for the choice of the procedure varied across stud-
es (shown in Table 2). The reasons provided were experience of thetraﬁed by the bio mark er status;  only RCTs
ect to ERCC1 by trial phase in identiﬁed studies.
laboratory, published literature, previous research experience (for
example pilot study), belief that the method of choice was  superior
or limitations imposed by the type of the available samples. For one
study it was declared that as with current knowledge there are no
antibodies that were isoform-speciﬁc, there was no rationale for
selection of the laboratory procedure.
4. Discussion
Application of stratiﬁed medicine in the real world requires that
the measurement of biomarkers and associated classiﬁcation algo-
rithms used to stratify patients follows a standardised protocol
within clinical trials, especially in the later phases. This ensures that
the evidence-base behind the stratiﬁed treatment is consistent and
valid, so that evidence-based decisions can be made about whether
a particular marker can be utilised in practice and, if so, how. We
have undertaken to research this issue via a speciﬁc case-study and
our aim was to investigate whether laboratory procedures used for
ERCC1 evaluation have become more standardised since a meta-
analysis published in 2011 found large variation [2].
There were 33 studies that met  our inclusion criteria, ranging
from phase 0 to phase IV. Fifteen of the studies used ERCC1 as
an integral part of their design: either to allocate treatment or to
stratify patients.
Our ﬁndings suggest that there was still large variation in both
the laboratory procedures and the tumour specimens used for
ERCC1 evaluation. Although they attempt to evaluate the same
biomarker, some small studies suggest that classifying patients
as ERCC1 positive and negative based on either RTqPCR or IHC
can lead to relatively large discrepancies [9,10]. For example, one
study investigating samples from 91 patients found that there was
a statistically signiﬁcant correlation between the ERCC1 mRNA and
protein expression levels. However when thresholds for classify-
ing patients as positive and negative were used, 33% of tumours
ERCC1 negative by RTqPCR were IHC positive and 32% IHC-negative
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Table  1
Details of RTqPCR used in studies where information was  returned.
Study Primers Reference gene(s) Threshold chosen
EUCTR2008-001764-36-IT (ITACA) Exons-spanning -Actin Median (using CT method, value
NR)
EUCTR2011-005267-24-IT (CONTEST) Not known (carried out by external
laboratory)
-Actin Ratio of ERCC1 to reference gene
transcripts: 0.14 (low), 13.4 (high),
Cut-off: 1.7
NCT00174629 (GILT Docetaxel) Designed according to their Ref. Seq in
https://www.ncbi.nlm.nih.gov/sites/
entrez?db/gene
-Actin Median (3.42 using CT method)
NCT00705549 “Primers have been previously
described in details (Papadaki et al BR J
Ca)”–paper could not be identiﬁed
-Actin and PGK Unclear (“the cut-off was based on the
a  chart analysis in >800 samples”)
NCT01194453 Primers spanning exons 7–9 of the
ENST00000300853 ERCC1 transcript:
5′TCGTCTCCCGGGTGACTG
3′and5′TTCTCTTGATGCGGCGATGAG 3
-Actin Median (value NR)
NCT00215930 (MADe IT) Intron-spanning primers Housekeeping gene 18SrRNA Above/below 8.7
ERCC 1 ass ess ment in identified studies ba sed on ongoing trials da taba ses and returned information
tumour  sample ass ay
20 15 10 5 phase 5 10 15 20
number of  studies nu mber of  studies
NR
0
I
II
III
IV
RTqPCR IHC
gene express ion NER polymorphism
multiple methods NR
not undertaken
biopsy
(FF )PE tumour tissue
surgical resection
surgical resection or biopsy
surgical resection, biopsy or cytology
NR
not undertaken
Fig. 3. ERCC1 evaluation in identiﬁed studies.
Table 2
Rationale for the choice of method of ERCC1 assessment in studies for which information was provided.
Published
literature
Previous own research
experience
Laboratory
experience
Believe method
most appropriate
Method suitable for
available samples
None NR
EUCTR2007-007639-17-GB (ET)
√ √
EUCTR2008-001764-36-IT (ITACA)
√
EUCTR2011-005267-24-IT (CONTEST)
√
NCT00174629 (GILT Docetaxel)
√
NCT00705549
√ √
NCT00775385 (TASTE)
√
NCT01194453
√
NCT01294280 (LACE-BIO)
√
NCT01781988 (PTINCLC)
√
NCT00215930 (MADE IT)
√ √
NCT00222404 (Pharmacogenoscan)
√
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umors were classed as ERCC1 positive using RTqPCR [11]. These
ndings suggest that both techniques may  not be interchangeable.
In our review even when the same assay was used, details of
he laboratory procedures and scoring systems appeared to vary.
his could further decrease the comparability of results between
tudies.
In the questionnaire, three out of ﬁve studies using IHC reported
sing the 8F1 antibody clone (Nomarkers). In two of the three stud-
es using the 8F1 clone, the dilution was reported and it was  the
ame. The use of the same antibody clone is crucial, as different
lones for the same antigen bind to different epitopes and can
herefore have different sensitivities and speciﬁcities [12,13].
There was large variation in the techniques used for RTqPCR,
specially in terms of the primers used, which can have a sub-
tantial impact on the results obtained using this method [14].
ive of the six studies used -actin as the reference standard (in
ne case together with another gene). The choice of a reference
tandard can be challenging and several publications have sug-
ested that levels of -actin expression can vary and may  not be a
ood reference standard [15,16]. The thresholds chosen in individ-
al studies also varied and, interestingly, three studies chose the
edian value obtained within the study. This seems to imply an
nderlying assumption that half of the patients in these studies are
esistant to platinum-based chemotherapy due to ERCC1 overex-
ression, however no reason for this assumption was provided.
Apart from using different assays, the methods of tumour sam-
le collection also varied. A small study using IHC for ERCC1
ssessment suggested that there might be a discrepancy in clas-
ifying patients’ ERCC1 expression levels depending on whether
umour tissue was obtained using biopsy or surgical resection [17].
nother study found discrepant results depending on whether
 tumour sample was obtained from the primary tumour or a
etastatic site [18].
Where reported, the proportion of patients classed as ERCC1
ositive ranged from 0.25 to 0.78. This would further suggest that
rocedures and criteria used in different studies for classifying
RCC1 expression levels do not produce comparable results. It is
owever possible that this variation is largely due to chance or, for
xample, prognostic properties of ERCC1.
On undertaking this review and questionnaire it was hypothe-
ised that the highest variation in the assays for ERCC1 evaluation
hould be seen in early phase trials and higher levels of standardis-
tion were expected for later phase studies. This was  however not
bserved. There was relatively large variation in the methods cho-
en for ERCC1 evaluation in phase II and III trials. There was also no
vidence of a trend suggesting certain methods of ERCC1 evalua-
ion became more popular at a particular time (for example due to
ublication of research suggesting one method could be superior).
With regards to the rationale for the choice of a particular
ethod, it was often motivated by experience of either the lab-
ratory or the researchers involved, although for three studies
ublished literature was also referred to.
As recent research suggests, there may  be no ERCC1 assay capa-
le of identifying a subgroup of patients more likely to beneﬁt
rom platinum-based chemotherapy. When tumour tissue samples
rom the same patients originally enrolled in the IALT trial were re-
valuated using exactly the same IHC procedures, 36% of patients
lassed as ERCC1 positive on one occasion were classed as nega-
ive on another.[7]. This raises the issue of unnecessarily enrolling
atients in trials where ERCC1 is, or was integral to trial design. This
otentially resulted in suboptimal treatment of these patients and
 suboptimal allocation of resources.
This systematic review is based on a relatively small sample
f studies and detailed information (from the questionnaire) was
imited to 16. The objective here was however not of quantitative
ature, but mainly to collect information on an example of large dis-ncer 92 (2016) 1–7
crepancies in evaluation of a potential predictive biomarker. There
is no reason to believe that this example is not representative of
at least some stratiﬁed medicine research, and the conclusions are
unlikely to change if further studies had been obtained (indeed,
heterogeneity in laboratory methods would likely increase).
From the perspective of reviewing evidence and implement-
ing biomarkers in clinical practice, it would be ideal if there was
one valid laboratory procedure used for biomarker evaluation in
all studies. However in practice this is unlikely, as the technology
in this ﬁeld is rapidly developing. New laboratory procedures are
being developed, which can offer more accurate biomarker evalu-
ation, as well as cost and time savings. It is therefore not surprising
that these are implemented in studies (although our review did
not identify an effect of dissemination of new technologies on the
choice of the laboratory procedures). Some of the variability may
also be due to the competition between different research groups
and differences in opinion on the suitability of a given assay. This
presents a challenge for implementing ﬁndings of studies using
different procedures in clinical practice, especially that, as some
research on ERCC1 suggests, the results obtained using different
procedures may  not be comparable. Therefore there is a need for
more research to ensure that procedures used to evaluate the same
predictive biomarker actually stratify patients into comparable
cohorts.
This example highlights the need for a more structured approach
to development and validation of biomarker tests prior to their use
in clinical trials. Although it may  appear that studies are using the
same assay, variation in important details of the laboratory pro-
cedures may  result in lack of comparability between results of
different studies.
It appears that the case of ERCC1 is not isolated. A potentially
similar situation has been recently identiﬁed in programmed-death
ligand 1 (PD-L1) testing in NSCLC, where multiple IHC assays using
different antibody clones are under development for four different
drugs and there is still uncertainty with regards to how well these
assays can predict patient response [19].
5. Conclusions
If a biomarker is to be used in clinical studies, especially later
phase, ideally its accuracy should be established. There also needs
to be consensus on a standardised validated protocol to be followed
in clinical trials, which would ensure there is a deﬁnitive biomarker
evaluation procedure to be used in future clinical practice. Existing
international research infrastructure could potentially be utilised
to accomplish consensus, however this may not be straightforward
due to individual opinions and experience.
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